<DOC>
	<DOCNO>NCT02335606</DOCNO>
	<brief_summary>Abatacept Registry Taiwan</brief_summary>
	<brief_title>Real World Effectiveness Abatacept Rheumatoid Arthritis Patients : Prospective , Single-arm , Open-label , Multi-center Observational Study Taiwan</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com ≥ 20 year age Who give inform consent Confirmed diagnosis RA ( defined American College Rheumatology revise 1987 criterion ) ≥ 4 criterion list ≥6 week study enrollment Who selfpay reimburse BNHI abatacept treatment With latent TB receive antiTB treatment ( INH 300 mg , QD ) 1 month prior use abatacept continuously total 9 month Willing follow Taiwan Risk Management Plan guideline require Taiwan health authority Are treat abatacept abatacept treatment naïve initiate abatacept therapy Pregnant breast feeding With active TB HBsAg ( + ) and/or AntiHCV ( + ) and/or HBV DNA ( + ) Have cancer ( patient treat sign cancer &gt; 10 year include ) Are allergic abatacept Enrolled RA clinical study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>